Within the $30 billion vaccine industry, technologies to promote intradermal vaccination are rapidly maturing and the first intradermal vaccines have reached the clinic. However, appropriate adjuvants for intradermal vaccination are still largely lacking. VIC investigators have discovered that a brief exposure of the skin to relatively low power (single Watt), near-infrared lasers before intradermal vaccination can significantly enhance vaccine immune responses without the usual inflammatory responses induced by conventional adjuvants. In an influenza challenge model in mice, this increase in immune response was linked to better survival outcomes. An NIH-funded project was recently successfully completed showing that such enhancement can be induced with small laser devices opening the door to practical commercial development of this approach. VIC is currently working with a newly-formed laser company Veralase (Middleton, MA.) to further develop this approach. VIC is also working with the University of California, Irvine to complete a pilot study on the safety and immunologic effects of NILA devices in humans.